Bromfenac (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Bromfenac" in Italian language version.

refsWebsite

Global rank Italian rank

17nih.gov

4^th place

9^th place

12doi.org

2^nd place

7^th place

11oadoi.org

799^th place

22^nd place

doi.org

dx.doi.org

Giuseppe Rovere, Francisco M. Nadal-Nicolás e Paloma Sobrado-Calvo, Topical Treatment With Bromfenac Reduces Retinal Gliosis and Inflammation After Optic Nerve Crush, in Investigative Ophthalmology & Visual Science, vol. 57, n. 14, 1º novembre 2016, pp. 6098–6106, DOI:10.1167/iovs.16-20425. URL consultato il 9 gennaio 2017.
LD. Waterbury, D. Silliman; T. Jolas, Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium., in Curr Med Res Opin, vol. 22, n. 6, Jun 2006, pp. 1133-40, DOI:10.1185/030079906X112471, PMID 16846546.
RH. Stewart, LR. Grillone; ML. Shiffman; ED. Donnenfeld; JA. Gow, The systemic safety of bromfenac ophthalmic solution 0.09%., in J Ocul Pharmacol Ther, vol. 23, n. 6, Dec 2007, pp. 601-12, DOI:10.1089/jop.2007.0040, PMID 18001250.
EC. Si, LM. Bowman; K. Hosseini, Pharmacokinetic comparisons of bromfenac in DuraSite and Xibrom., in J Ocul Pharmacol Ther, vol. 27, n. 1, Feb 2011, pp. 61-6, DOI:10.1089/jop.2010.0103, PMID 21332395.
GA. Baklayan, HM. Patterson; CK. Song; JA. Gow; TR. McNamara, 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits., in J Ocul Pharmacol Ther, vol. 24, n. 4, Aug 2008, pp. 392-8, DOI:10.1089/jop.2007.0082, PMID 18665811.
ED. Donnenfeld, EJ. Holland; RH. Stewart; JA. Gow; LR. Grillone, Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation., in Ophthalmology, vol. 114, n. 9, Sep 2007, pp. 1653-62, DOI:10.1016/j.ophtha.2006.12.029, PMID 17445902.
M. Miyanaga, T. Miyai; R. Nejima; Y. Maruyama; K. Miyata; S. Kato, Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery., in Acta Ophthalmol, vol. 87, n. 3, maggio 2009, pp. 300-5, DOI:10.1111/j.1755-3768.2008.01433.x, PMID 19183412.
SM. Silverstein, MG. Cable; E. Sadri; JH. Peace; R. Fong; SP. Chandler; JA. Gow; SM. Klier; TR. McNamara; DE. Beahm; JD. Boyce, Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain., in Curr Med Res Opin, vol. 27, n. 9, Sep 2011, pp. 1693-703, DOI:10.1185/03007995.2011.597663, PMID 21751945.
E. Uchio, Y. Itoh; K. Kadonosono, Topical bromfenac sodium for long-term management of vernal keratoconjunctivitis., in Ophthalmologica, vol. 221, n. 3, 2007, pp. 153-8, DOI:10.1159/000099294, PMID 17440276.
M. Miyake-Kashima, Y. Takano; M. Tanaka; Y. Satake; T. Kawakita; M. Dogru; N. Asano-Kato; K. Fukagawa; H. Fujishima, Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis., in Jpn J Ophthalmol, vol. 48, n. 6, pp. 587-90, DOI:10.1007/s10384-004-0127-2, PMID 15592786.
H. Isawi, DK. Dhaliwal, Corneal melting and perforation in Stevens Johnson syndrome following topical bromfenac use., in J Cataract Refract Surg, vol. 33, n. 9, Sep 2007, pp. 1644-6, DOI:10.1016/j.jcrs.2007.04.041, PMID 17720085.
ED. Donnenfeld, A. Donnenfeld, Global experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug., in Int Ophthalmol Clin, vol. 46, n. 4, 2006, pp. 21-40, DOI:10.1097/01.iio.0000212134.83513.11, PMID 17060789.

nih.gov

ncbi.nlm.nih.gov

Giuseppe Rovere, Francisco M. Nadal-Nicolás e Paloma Sobrado-Calvo, Topical Treatment With Bromfenac Reduces Retinal Gliosis and Inflammation After Optic Nerve Crush, in Investigative Ophthalmology & Visual Science, vol. 57, n. 14, 1º novembre 2016, pp. 6098–6106, DOI:10.1167/iovs.16-20425. URL consultato il 9 gennaio 2017.
LF. Sancilio, JC. Nolan; LE. Wagner; JW. Ward, The analgesic and antiinflammatory activity and pharmacologic properties of bromfenac., in Arzneimittelforschung, vol. 37, n. 5, maggio 1987, pp. 513-9, PMID 3497637.
J. Ruiz, M. López; J. Milà; E. Lozoya; JJ. Lozano; R. Pouplana, QSAR and conformational analysis of the antiinflammatory agent amfenac and analogues., in J Comput Aided Mol Des, vol. 7, n. 2, Apr 1993, pp. 183-98, PMID 8320556.
LD. Waterbury, D. Silliman; T. Jolas, Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium., in Curr Med Res Opin, vol. 22, n. 6, Jun 2006, pp. 1133-40, DOI:10.1185/030079906X112471, PMID 16846546.
RH. Stewart, LR. Grillone; ML. Shiffman; ED. Donnenfeld; JA. Gow, The systemic safety of bromfenac ophthalmic solution 0.09%., in J Ocul Pharmacol Ther, vol. 23, n. 6, Dec 2007, pp. 601-12, DOI:10.1089/jop.2007.0040, PMID 18001250.
EC. Si, LM. Bowman; K. Hosseini, Pharmacokinetic comparisons of bromfenac in DuraSite and Xibrom., in J Ocul Pharmacol Ther, vol. 27, n. 1, Feb 2011, pp. 61-6, DOI:10.1089/jop.2010.0103, PMID 21332395.
GA. Baklayan, HM. Patterson; CK. Song; JA. Gow; TR. McNamara, 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits., in J Ocul Pharmacol Ther, vol. 24, n. 4, Aug 2008, pp. 392-8, DOI:10.1089/jop.2007.0082, PMID 18665811.
ED. Donnenfeld, EJ. Holland; RH. Stewart; JA. Gow; LR. Grillone, Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation., in Ophthalmology, vol. 114, n. 9, Sep 2007, pp. 1653-62, DOI:10.1016/j.ophtha.2006.12.029, PMID 17445902.
M. Miyanaga, T. Miyai; R. Nejima; Y. Maruyama; K. Miyata; S. Kato, Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery., in Acta Ophthalmol, vol. 87, n. 3, maggio 2009, pp. 300-5, DOI:10.1111/j.1755-3768.2008.01433.x, PMID 19183412.
SM. Silverstein, MG. Cable; E. Sadri; JH. Peace; R. Fong; SP. Chandler; JA. Gow; SM. Klier; TR. McNamara; DE. Beahm; JD. Boyce, Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain., in Curr Med Res Opin, vol. 27, n. 9, Sep 2011, pp. 1693-703, DOI:10.1185/03007995.2011.597663, PMID 21751945.
E. Uchio, Y. Itoh; K. Kadonosono, Topical bromfenac sodium for long-term management of vernal keratoconjunctivitis., in Ophthalmologica, vol. 221, n. 3, 2007, pp. 153-8, DOI:10.1159/000099294, PMID 17440276.
M. Miyake-Kashima, Y. Takano; M. Tanaka; Y. Satake; T. Kawakita; M. Dogru; N. Asano-Kato; K. Fukagawa; H. Fujishima, Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis., in Jpn J Ophthalmol, vol. 48, n. 6, pp. 587-90, DOI:10.1007/s10384-004-0127-2, PMID 15592786.
T. Ogawa, T. Sakaue; T. Terai; C. Fukiage, [Effects of bromfenac sodium, non-steroidal anti-inflammatory drug, on acute ocular inflammation]., in Nihon Ganka Gakkai Zasshi, vol. 99, n. 4, Apr 1995, pp. 406-11, PMID 7741052.
H. Isawi, DK. Dhaliwal, Corneal melting and perforation in Stevens Johnson syndrome following topical bromfenac use., in J Cataract Refract Surg, vol. 33, n. 9, Sep 2007, pp. 1644-6, DOI:10.1016/j.jcrs.2007.04.041, PMID 17720085.
T. Asai, T. Nakagami; M. Mochizuki; N. Hata; T. Tsuchiya; Y. Hotta, Three cases of corneal melting after instillation of a new nonsteroidal anti-inflammatory drug., in Cornea, vol. 25, n. 2, Feb 2006, pp. 224-7, PMID 16371788.
ED. Donnenfeld, A. Donnenfeld, Global experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug., in Int Ophthalmol Clin, vol. 46, n. 4, 2006, pp. 21-40, DOI:10.1097/01.iio.0000212134.83513.11, PMID 17060789.
DA. Walsh, HW. Moran; DA. Shamblee; IM. Uwaydah; WJ. Welstead; LF. Sancilio; WN. Dannenburg, Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues., in J Med Chem, vol. 27, n. 11, Nov 1984, pp. 1379-88, PMID 6436487.

oadoi.org

LD. Waterbury, D. Silliman; T. Jolas, Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium., in Curr Med Res Opin, vol. 22, n. 6, Jun 2006, pp. 1133-40, DOI:10.1185/030079906X112471, PMID 16846546.
RH. Stewart, LR. Grillone; ML. Shiffman; ED. Donnenfeld; JA. Gow, The systemic safety of bromfenac ophthalmic solution 0.09%., in J Ocul Pharmacol Ther, vol. 23, n. 6, Dec 2007, pp. 601-12, DOI:10.1089/jop.2007.0040, PMID 18001250.
EC. Si, LM. Bowman; K. Hosseini, Pharmacokinetic comparisons of bromfenac in DuraSite and Xibrom., in J Ocul Pharmacol Ther, vol. 27, n. 1, Feb 2011, pp. 61-6, DOI:10.1089/jop.2010.0103, PMID 21332395.
GA. Baklayan, HM. Patterson; CK. Song; JA. Gow; TR. McNamara, 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits., in J Ocul Pharmacol Ther, vol. 24, n. 4, Aug 2008, pp. 392-8, DOI:10.1089/jop.2007.0082, PMID 18665811.
ED. Donnenfeld, EJ. Holland; RH. Stewart; JA. Gow; LR. Grillone, Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation., in Ophthalmology, vol. 114, n. 9, Sep 2007, pp. 1653-62, DOI:10.1016/j.ophtha.2006.12.029, PMID 17445902.
M. Miyanaga, T. Miyai; R. Nejima; Y. Maruyama; K. Miyata; S. Kato, Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery., in Acta Ophthalmol, vol. 87, n. 3, maggio 2009, pp. 300-5, DOI:10.1111/j.1755-3768.2008.01433.x, PMID 19183412.
SM. Silverstein, MG. Cable; E. Sadri; JH. Peace; R. Fong; SP. Chandler; JA. Gow; SM. Klier; TR. McNamara; DE. Beahm; JD. Boyce, Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain., in Curr Med Res Opin, vol. 27, n. 9, Sep 2011, pp. 1693-703, DOI:10.1185/03007995.2011.597663, PMID 21751945.
E. Uchio, Y. Itoh; K. Kadonosono, Topical bromfenac sodium for long-term management of vernal keratoconjunctivitis., in Ophthalmologica, vol. 221, n. 3, 2007, pp. 153-8, DOI:10.1159/000099294, PMID 17440276.
M. Miyake-Kashima, Y. Takano; M. Tanaka; Y. Satake; T. Kawakita; M. Dogru; N. Asano-Kato; K. Fukagawa; H. Fujishima, Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis., in Jpn J Ophthalmol, vol. 48, n. 6, pp. 587-90, DOI:10.1007/s10384-004-0127-2, PMID 15592786.
H. Isawi, DK. Dhaliwal, Corneal melting and perforation in Stevens Johnson syndrome following topical bromfenac use., in J Cataract Refract Surg, vol. 33, n. 9, Sep 2007, pp. 1644-6, DOI:10.1016/j.jcrs.2007.04.041, PMID 17720085.
ED. Donnenfeld, A. Donnenfeld, Global experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug., in Int Ophthalmol Clin, vol. 46, n. 4, 2006, pp. 21-40, DOI:10.1097/01.iio.0000212134.83513.11, PMID 17060789.